A common single nucleotide polymorphism A118G of the μ opioid receptor alters its N-glycosylation and protein stability.
- Authors
- Huang, Peng; Chen, Chongguang; Mague, Stephen D; Blendy, Julie A; Liu-Chen, Lee-Yuan
- Year
- 2012
- Journal
- The Biochemical journal
- PMID
- 21864297
- DOI
- 10.1042/BJ20111050
- PMCID
- PMC3923516
The A118G SNP (single nucleotide polymorphism) of the hMOPR [human MOPR (μ opioid receptor)] gene OPRM1 results in an amino acid substitution (N40D). Subjects homozygous for the 118G allele have been reported to require higher morphine doses to achieve adequate analgesia, and the 118G allele is more prevalent among drug abusers. However, changes in the MOPR protein associated with this SNP are unknown. Using a knockin mouse model (G/G mice; mice homozygous for the 112G allele of MOPR) that possesses the equivalent nucleotide/amino acid substitution (A112G; N38D) of the A118G SNP in the hMOPR gene, we investigated the N-linked glycosylation status of thalamic and striatal MOPR in G/G mice compared with A/A mice (wild-type mice homozygous for the 112A allele of MOPR). The molecular mass of MOPR determined by immunoblotting was lower in G/G mice than in A/A mice. Following treatment with peptide N-glycosidase F, which removes all N-linked glycans, both MOPR variants had an identical molecular mass, indicating that this discrepancy was due to a lower level of N-glycosylation of the MOPR in G/G mice. In Chinese-hamster ovary cells stably expressing hMOPRs, 118G/Asp40-hMOPR had a lower molecular mass than 118A/Asn40-hMOPR, which was similarly due to differential N-glycosylation. Pulse-chase studies revealed that the half-life of the mature form of 118G/Asp40-hMOPR (~12 h) was shorter than that of 118A/Asn40-hMOPR (~28 h). Thus the A118G SNP reduces MOPR N-glycosylation and protein stability.
The amino acid sequences of the N-terminal domains of human and mouse MOPRsPotential N-linked glycosylation sites are in red. The common amino acids are highlighted in yellow. The conservative substitutions are shaded in grey.
Immunoblotting of the MOPRs in the thalami and striata of A/A mice, G/G mice and MOPR(-/-) miceBrain membranes were prepared from thalami or striata of adult female mice. Membrane proteins were resolved with 8% SDS–PAGE and immunoblotted with anti-mu C (1:5000), an affinity-purified polyclonal anti-MOR antibody we generated, as described in Materials and Methods. Each figure is a representative of the three independent experiments performed with tissues from different cohorts of female mice. Male mice yielded similar results (not shown).
Deglycosylation with PNGase F of MOPRs from thalami of A/A and G/G miceThalamic membranes of A/A or G/G mice (mixed gender: 50% of each sex) were pooled and solubilized with 2% Triton X-100. The solubilized preparations were incubated with the wheat germ lectin (WGL) Sepharose 6MB beads and the bound glycoproteins were eluted with 2 × Laemmli sample buffer. The amount of eluate was adjusted to have similar MOPR levels. The eluate was left untreated or treated with PNGase F, resolved with 8% SDS–PAGE, and immunoblotted with anti-mu C (1:5000) as described in Fig.1. This figure is from one of the two independent experiments performed with similar results.
Immunoblotting of the wild-type and A118G mutant of hMOPR (A118/N40-hMOPR and G118/D40-hMOPR, respectively) stably expressed in CHO and HEK293 cellsCHO cells were stably transfected with 3HA tagged A118/N40- or G118/D40-hMOPR cDNA in the mammalian expression vector pcDNA3. Cells from stable mixed clones were collected and the protein contents resolved with 8% SDS–PAGE and immunoblotted with monoclonal anti-HA antibody HA.11. After stripping, the same blot was then processed for immunoblotting with mouse anti-GAPDH-HRP-conjugated. Each figure is from one of two independent experiments performed with similar results.
Deglycosylation with PNGase F of the wild-type and A118G mutant of hMOPR (A118/N40-hMOPR and G118/N40-hMOPR, respectively) stably expressed in CHO cellsCells were solubilized with 2% Triton X-100. The A118/N40- or G118/D40-hMOPR was partially purified by WGL affinity chromatography, left untreated or treated with PNGase F and resolved with 8% SDS–PAGE as described in the Fig. 3 legend, and immunoblotted with HA.11 described in the Fig.4 legend. The amount of eluate was adjusted to have similar MOPR levels. Each figure shown is from one of three independent experiments with similar results.
Pulse-chase experiments of wildtype and A118G mutant of hMOPR (A118/N40-hMOPR and G118/D40-hMOPR, respectively) stably expressed in CHO cellsCells were metabolically labeled with [35S]Met/Cys at 37°C for 60 min (pulse). Medium was aspirated, and cells were incubated with complete medium (chase) for specified time periods. Cells were solubilized and immunoprecipitated with HA.11 antibody twice in tandem. Immunoprecipitated materials were resolved with SDS-PAGE and gels were dried. The gels were then exposed to a storage phosphor screen for 5 days, and the autoradiograms were acquired. (A) shows a representative autoradiogram. The intensities of [35S]-labeled protein bands were analyzed and quantified for the mature forms (B) and the precursors (C) as described in Methods. The signals for mature forms and precursors were normalized against their maximal signals observed at time points 2h and 0h, respectively. The experiment was performed three times with similar results. Each value in (B) and (C) is mean ± s.e.m. (n=3).
| # | Section | Preview |
|---|---|---|
| 20 | Results — The relative molecular mass (Mr) of MOPR in G/G mice was lower than that in A/A mice, which is due to differences in N-glycosylation of MOPR | Immunoblotting of the MOPR was performed on membranes of the thalamus and striatum of female mice.… |
| 21 | Results — The relative molecular mass (Mr) of MOPR in G/G mice was lower than that in A/A mice, which is due to differences in N-glycosylation of MOPR | (Fig. 2, right panel, lane 1 vs lane 3). Similarly, the striatal MOPR band in G/G mice had a lower… |
| 22 | Results — The relative molecular mass (Mr) of MOPR in G/G mice was lower than that in A/A mice, which is due to differences in N-glycosylation of MOPR | We then tested the hypothesis that the differences in the Mr's of the MOPRs in A/A and G/G are due… |
| 23 | Results — The relative molecular mass (Mr) of MOPR in G/G mice was lower than that in A/A mice, which is due to differences in N-glycosylation of MOPR | and 2), respectively. Treatment of the WGL affinity-purified materials with PNGase F resulted in an… |
| 24 | Results — The Mr of G118/D40-hMOPR was lower than that of A118/N40-hMOPR, due to different N-glycosylation, when both were stably expressed in cultured cells | N-linked glycosylation in 7TMRs has been shown to play important role in proper folding and… |
| 25 | Results — The Mr of G118/D40-hMOPR was lower than that of A118/N40-hMOPR, due to different N-glycosylation, when both were stably expressed in cultured cells | CHO cells stably expressing A118/N40-hMOPR or G118/D40-hMOPR were solubilized with Triton X-100, and… |
| 26 | Results — The half-life of G118/D40-hMOPR was shorter than that of A118/N40-hMOPR expressed in CHO cells | We then examined if the A118G SNP affected maturation and stability of the MOPR with pulse-chase… |
| 27 | Results — The half-life of G118/D40-hMOPR was shorter than that of A118/N40-hMOPR expressed in CHO cells | both hMOPR variants (Fig. 6A). With their peak levels as 100%, the levels of the mature forms of… |
| 28 | Discussion | The current studies provided the first experimental evidence that A118G SNP reduced the N-linked… |
| 29 | Discussion — Decreased Mr of MOPR by A118G/A112G is indicative of its reduced N-glycosylation | We found by immunoblotting that G112/D38-MOPR (G/G mice) had lower Mr than A112/N38-MOPR (A/A mice)… |
| 30 | Discussion — Reduced N-glycosylation of MOPR by A118G mutation results in its lower protein stability in CHO cells | It is generally accepted that N-glycans are important to the overall stability of glycoproteins… |
| 31 | Discussion — Is the A118G/A112G-induced lower protein stability of MOPR related to the lower protein level? | The mature forms of the G118/D40-hMOPR stably expressed in CHO cells had a shorter half-life than… |
| 32 | Discussion — Is the A118G/A112G-induced lower protein stability of MOPR related to the lower protein level? | were observed in the striatum and the ventral tegmental area [19]. Moreover, in the human carriers… |
| 33 | Discussion — Is the A118G/A112G-induced lower protein stability of MOPR related to the lower protein level? | by [3H]DAMGO binding and/or immunoblotting, but did not change protein expression of the hMOPR in… |
| 34 | Discussion — Is the A118G/A112G-induced lower protein stability of MOPR related to the lower protein level? | from the brain region-specific glycosylation of Asn residues and/or different N-glycan compositions… |
| 35 | Discussion — Is the A118G/A112G-induced lower protein stability of MOPR related to the lower protein level? | Similarly, A1 18G/A112G decreased or did not change MOPR mRNA levels depending on brain regions. In… |
| 36 | Discussion — Reduced N-glycosylation of MOPR by A118G SNP has little effect on binding affinities of opioid ligands | Regarding the binding affinities of exogenous ligands, including DAMGO, morphine,… |
| 37 | Discussion — Detection of endogenous MOPR in brain by western blot | Our experience demonstrates that it is difficult to identify endogenous MOPR by immunoblotting, in… |
| 38 | Discussion — Detection of endogenous MOPR in brain by western blot | with anti-MOPR antibodies [18,27,30]. The rigor and convergence of pharmacological and biochemical… |
| 39 | Discussion — Detection of endogenous MOPR in brain by western blot | Our concerns about the reliability of the anti-MOPR antibodies, several of which are commercially… |
No entities extracted from this document yet.
No uploaded files.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Buprenorphine Pharmacodynamics: A Bridge to Understanding Buprenorphine Clinical Benefits. | Davis M | — | 2025 | → |
| Do Diabetes and Genetic Polymorphisms in the <i>COMT</i> and <i>OPRM1</i> Genes Modulate the Postoperative Opioid Demand and Pain Perception in Osteoarthritis Patients After Total Knee and Hip Arthroplasty? | Jurewicz A et al. | — | 2025 | → |
| <i>Kappa</i>-opioid receptor gene (<i>OPRK1</i>) variations associated with opioid abstinence behaviors among chronic heroin users. | Greenwald MK et al. | — | 2025 | → |
| Mechanisms governing GPCR anterograde transport. | Assoumou K et al. | — | 2025 | → |
| Modulating vertebrate physiology by genomic fine-tuning of GPCR functions. | Schöneberg T | — | 2025 | → |
| Pharmacogenetics of opioid medications for relief of labor pain and post-cesarean pain: a systematic review and meta-analysis. | Giacon M et al. | — | 2025 | → |
| Functional differences in the mu opioid receptor SNP 118A>G are dependent on receptor splice-variant and agonist-specific recruitment of β-arrestin. | Patrick C et al. | — | 2024 | → |
| Genetic influence on treatment outcomes in patients with pain-related temporomandibular disorders. | Zlendić M et al. | — | 2024 | → |
| Ketamine: Mechanisms and Relevance to Treatment of Depression. | Kim JW et al. | — | 2024 | → |
| Neural Network Connectivity Following Opioid Dependence is Altered by a Common Genetic Variant in the µ-Opioid Receptor, <i>OPRM1</i> A118G. | Xie Y et al. | — | 2024 | → |
| Pharmacogenetics of Biochemically Verified Abstinence in an Opioid Agonist Therapy Randomized Clinical Trial of Methadone and Buprenorphine/Naloxone. | Kazi I et al. | — | 2024 | → |
| S-nitrosoglutathione reductase alleviates morphine analgesic tolerance by restricting PKCα S-nitrosation. | Su LY et al. | — | 2024 | → |
| One immune system plays many parts: The dynamic role of the immune system in chronic pain and opioid pharmacology. | Mustafa S et al. | — | 2023 | → |
| <i>ABCB1</i> and <i>OPRM1</i> single-nucleotide polymorphisms collectively modulate chronic shoulder pain and dysfunction in South African breast cancer survivors. | Firfirey F et al. | — | 2022 | → |
| Knock-In Mouse Models to Investigate the Functions of Opioid Receptors <i>in vivo</i>. | Degrandmaison J et al. | — | 2022 | → |
| No Association between Genetic Variants of the <i>COMT</i> and <i>OPRM1</i> Genes and Pain Perception among Patients Undergoing Total Hip or Knee Arthroplasty for Primary Osteoarthritis. | Jurewicz A et al. | — | 2022 | → |
| Fentanyl-Induced Respiratory Depression: A Narrative Review on the Possible Single-Nucleotide Polymorphism. | Udayakumar P et al. | — | 2021 | → |
| Mutations in G Protein-Coupled Receptors: Mechanisms, Pathophysiology and Potential Therapeutic Approaches. | Schöneberg T et al. | — | 2021 | → |
| The association between selected genetic variants and individual differences in experimental pain. | Lie MU et al. | — | 2021 | → |
| The Life Cycle of the Mu-Opioid Receptor. | Cuitavi J et al. | — | 2021 | → |
| Translational Research in Nicotine Addiction. | Fisher ML et al. | — | 2021 | → |
| Addiction associated N40D mu-opioid receptor variant modulates synaptic function in human neurons. | Halikere A et al. | — | 2020 | → |
| A Truncated Six Transmembrane Splice Variant MOR-1G Enhances Expression of the Full-Length Seven Transmembrane <i>μ-</i>Opioid Receptor through Heterodimerization. | Zhang T et al. | — | 2020 | → |
| Effects of Mu-Opiate Receptor Gene Polymorphism rs1799971 (A118G) on the Antidepressant and Dissociation Responses in Esketamine Nasal Spray Clinical Trials. | Saad Z et al. | — | 2020 | → |
| Etorphine-Azaperone Immobilisation for Translocation of Free-Ranging Masai Giraffes (<i>Giraffa Camelopardalis Tippelskirchi</i>): A Pilot Study. | Vitali F et al. | — | 2020 | → |
| Murine model of OPRM1 A118G alters oxycodone self-administration and locomotor activation, but not conditioned place preference. | Collins D et al. | — | 2020 | → |
| On the path towards personalized medicine: Implications of pharmacogenetic studies of alcohol use disorder medications. | Nieto SJ et al. | — | 2020 | → |
| Post-translational Modifications of Opioid Receptors. | Lemos Duarte M et al. | — | 2020 | → |
| Relapse-like behavior in a mouse model of the OPRM1 (mu-opioid receptor) A118G polymorphism: Examination with intravenous oxycodone self-administration. | Zhang Y et al. | — | 2020 | → |
| Systematic Review and Meta-Analysis of Genetic Risk of Developing Chronic Postsurgical Pain. | Chidambaran V et al. | — | 2020 | → |
| An update on the safety of prescribing opioids in pediatrics. | Parikh JM et al. | — | 2019 | → |
| Binge-Like Eating Is Not Influenced by the Murine Model of <i>OPRM1</i> A118G Polymorphism. | Sachdeo BLY et al. | — | 2019 | → |
| Candidate gene analyses for acute pain and morphine analgesia after pediatric day surgery: African American versus European Caucasian ancestry and dose prediction limits. | Li J et al. | — | 2019 | → |
| Opioids in cancer-related pain: current situation and outlook. | George B et al. | — | 2019 | → |
| Synaptic Regulation by OPRM1 Variants in Reward Neurocircuitry. | Popova D et al. | — | 2019 | → |
| Dynamic lateral organization of opioid receptors (kappa, mu<sub>wt</sub> and mu<sub>N40D</sub> ) in the plasma membrane at the nanoscale level. | Rogacki MK et al. | — | 2018 | → |
| Increased ethanol drinking in "humanized" mice expressing the mu opioid receptor A118G polymorphism are mediated through sex-specific mechanisms. | Henderson-Redmond AN et al. | — | 2018 | → |
| Molecular Genetics and New Medication Strategies for Opioid Addiction. | Hurd YL et al. | — | 2018 | → |
| MPDU1 regulates CEACAM1 and cell adhesion in vitro and in vivo. | Bennett DC et al. | — | 2018 | → |
| Oprm1 A112G, a single nucleotide polymorphism, alters expression of stress-responsive genes in multiple brain regions in male and female mice. | Collins D et al. | — | 2018 | → |
| OPRM1 A118G and serum β-endorphin interact with sex and digit ratio (2D:4D) to influence risk and course of alcohol dependence. | Gegenhuber B et al. | — | 2018 | → |
| A genetic polymorphism repurposes the G-protein coupled and membrane-associated estrogen receptor GPER to a transcription factor-like molecule promoting paracrine signaling between stroma and breast carcinoma cells. | Pupo M et al. | — | 2017 | → |
| Analysis of Serum Cytokines and Single-Nucleotide Polymorphisms of SOD1, SOD2, and CAT in Erysipelas Patients. | Emene CC et al. | — | 2017 | → |
| Convergent Balancing Selection on the Mu-Opioid Receptor in Primates. | Sweeney CG et al. | — | 2017 | → |
| Genetic variation in the behavioral effects of buprenorphine in female mice derived from a murine model of the OPRM1 A118G polymorphism. | Browne CA et al. | — | 2017 | → |
| Genetic Variation of the Mu Opioid Receptor (OPRM1) and Dopamine D2 Receptor (DRD2) is Related to Smoking Differences in Patients with Schizophrenia but not Bipolar Disorder. | Hirasawa-Fujita M et al. | — | 2017 | → |
| Production of G protein-coupled receptors in an insect-based cell-free system. | Sonnabend A et al. | — | 2017 | → |
| The μ-opioid receptor nonsynonymous variant 118A>G is associated with prolonged abstinence from heroin without agonist treatment. | Levran O et al. | — | 2017 | → |
| Alcohol addiction and the mu-opioid receptor. | Berrettini W | — | 2016 | → |
| An early granulocyte colony-stimulating factor treatment attenuates neuropathic pain through activation of mu opioid receptors on the injured nerve. | Liao MF et al. | — | 2016 | → |
| Association of the OPRM1 Variant rs1799971 (A118G) with Non-Specific Liability to Substance Dependence in a Collaborative de novo Meta-Analysis of European-Ancestry Cohorts. | Schwantes-An TH et al. | — | 2016 | → |
| Effects of fentanyl administration on locomotor response in horses with the G57C μ-opioid receptor polymorphism. | Wetmore LA et al. | — | 2016 | → |
| Morphine-induced antinociception and reward in "humanized" mice expressing the mu opioid receptor A118G polymorphism. | Henderson-Redmond AN et al. | — | 2016 | → |
| Opioid Antagonists and the A118G Polymorphism in the μ-Opioid Receptor Gene: Effects of GSK1521498 and Naltrexone in Healthy Drinkers Stratified by OPRM1 Genotype. | Ziauddeen H et al. | — | 2016 | → |
| Opioid neuroscience for addiction medicine: From animal models to FDA approval for alcohol addiction. | Berrettini W | — | 2016 | → |
| The AC/AG Diplotype for the 118A>G and IVS2 + 691G>C Polymorphisms of OPRM1 Gene is Associated with Sleep Quality Among Opioid-Dependent Patients on Methadone Maintenance Therapy. | Zahari Z et al. | — | 2016 | → |
| Association of OPRM1 A118G variant with risk of morphine-induced respiratory depression following spine fusion in adolescents. | Chidambaran V et al. | — | 2015 | → |
| Association of single nucleotide polymorphisms of ABCB1, OPRM1 and COMT with pain perception in cancer patients. | Wang XS et al. | — | 2015 | → |
| Cellular signalling of non-synonymous single-nucleotide polymorphisms of the human μ-opioid receptor (OPRM1). | Knapman A et al. | — | 2015 | → |
| Detection of mu opioid receptor (MOPR) and its glycosylation in rat and mouse brains by western blot with anti-μC, an affinity-purified polyclonal anti-MOPR antibody. | Huang P et al. | — | 2015 | → |
| Functional mu opioid receptor polymorphism (OPRM1 A(118) G) associated with heroin use outcomes in Caucasian males: A pilot study. | Woodcock EA et al. | — | 2015 | → |
| Mouse model of OPRM1 (A118G) polymorphism increases sociability and dominance and confers resilience to social defeat. | Briand LA et al. | — | 2015 | → |
| Receptor Reserve Moderates Mesolimbic Responses to Opioids in a Humanized Mouse Model of the OPRM1 A118G Polymorphism. | Robinson JE et al. | — | 2015 | → |
| Regional brain [(11)C]carfentanil binding following tobacco smoking. | Domino EF et al. | — | 2015 | → |
| The mu opioid receptor: A new target for cancer therapy? | Singleton PA et al. | — | 2015 | → |
| A heroin addiction severity-associated intronic single nucleotide polymorphism modulates alternative pre-mRNA splicing of the μ opioid receptor gene OPRM1 via hnRNPH interactions. | Xu J et al. | — | 2014 | → |
| A logistic equation to determine the validity of tramadol from related gene polymorphisms and psychological factors. | Zhao Q et al. | — | 2014 | → |
| Brain region- and sex-specific alterations in DAMGO-stimulated [(35) S]GTPγS binding in mice with Oprm1 A112G. | Wang YJ et al. | — | 2014 | → |
| Buprenorphine signalling is compromised at the N40D polymorphism of the human μ opioid receptor in vitro. | Knapman A et al. | — | 2014 | → |
| Endogenous opioid system influences depressive reactions to socially painful targeted rejection life events. | Slavich GM et al. | — | 2014 | → |
| How much oxycodone is needed for adequate analgesia after breast cancer surgery: effect of the OPRM1 118A>G polymorphism. | Cajanus K et al. | — | 2014 | → |
| Pharmacogenomics of methadone maintenance treatment. | Somogyi AA et al. | — | 2014 | → |
| Solubilization and reconstitution of the mu-opioid receptor expressed in human neuronal SH-SY5Y and CHO cells. | Talmont F et al. | — | 2014 | → |
| Subjective health complaints in patients with lumbar radicular pain and disc herniation are associated with a sex - OPRM1 A118G polymorphism interaction: a prospective 1-year observational study. | Hasvik E et al. | — | 2014 | → |
| Targeting opioid receptors with pharmacological chaperones. | Petäjä-Repo UE et al. | — | 2014 | → |
| A G protein-coupled receptor (GPCR) in red: live cell imaging of the kappa opioid receptor-tdTomato fusion protein (KOPR-tdT) in neuronal cells. | Huang P et al. | — | 2013 | → |
| Consequences of the 118A>G polymorphism in the OPRM1 gene: translation from bench to bedside? | Mura E et al. | — | 2013 | → |
| Endogenous opiates and behavior: 2012. | Bodnar RJ | — | 2013 | → |
| Functional characteristics of the naked mole rat μ-opioid receptor. | Busch-Dienstfertig M et al. | — | 2013 | → |
| Gene polymorphisms of OPRM1 A118G and ABCB1 C3435T may influence opioid requirements in Chinese patients with cancer pain. | Gong XD et al. | — | 2013 | → |
| Influence of OPRM1 Asn40Asp variant (A118G) on [11C]carfentanil binding potential: preliminary findings in human subjects. | Weerts EM et al. | — | 2013 | → |
| Opioid pharmacogenetics of alcohol addiction. | Berrettini W | — | 2013 | → |
| Recent developments in the study of opioid receptors. | Cox BM | — | 2013 | → |
| Cellulose degradation by Sulfolobus solfataricus requires a cell-anchored endo-β-1-4-glucanase. | Girfoglio M et al. | — | 2012 | → |
| Influence of the OPRM1 A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone. | Setiawan E et al. | — | 2012 | → |
| Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics. | Kreek MJ et al. | — | 2012 | → |
| Pain intensity the first year after lumbar disc herniation is associated with the A118G polymorphism in the opioid receptor mu 1 gene: evidence of a sex and genotype interaction. | Olsen MB et al. | — | 2012 | → |
| Potentiation of dopamine D1-like receptor signaling by concomitant activation of δ- and μ-opioid receptors in mouse medial prefrontal cortex. | Olianas MC et al. | — | 2012 | → |
| Reduced expression of the μ opioid receptor in some, but not all, brain regions in mice with OPRM1 A112G. | Wang YJ et al. | — | 2012 | → |